SportGait Partners With the Carrick Institute, Incorporating Cutting-Edge Concussion Support and Recovery Technology
October 26, 2022 14:00 ET
|
SportGait
WILMINGTON, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- SportGait, the brain wellness and medical technology company, proudly announced today a partnership with The Carrick Institute, world leader in...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
October 20, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical...
electroCore Provides Select Third Quarter 2022 Financial Guidance
October 14, 2022 16:01 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
October 11, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
October 11, 2022 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique...
Odyssey Health, Inc. Provides Recap on Concussion Drug Development
October 06, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
September 30, 2022 18:28 ET
|
Odyssey Health, Inc
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
September 28, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
New Study Reveals Effective Treatment for Children Suffering From Persistent Post-Concussion Syndrome
September 23, 2022 13:51 ET
|
Aviv Clinics
ORLANDO, Fla., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Today, Aviv Clinics highlights a new study published in Scientific Reports showing an effective treatment to heal damaged brain tissue and relieve...
electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
September 21, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...